Eris Lifesciences is currently trading at Rs. 1024.50, up by 18.85 points or 1.87% from its previous closing of Rs. 1005.65 on the BSE.

The scrip opened at Rs. 1002.00 and has touched a high and low of Rs. 1026.60 and Rs. 1002.00 respectively. So far 3407 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1053.90 on 10-Jun-2024 and a 52 week low of Rs. 648.70 on 15-Jun-2023.

Last one week high and low of the scrip stood at Rs. 1053.90 and Rs. 913.65 respectively. The current market cap of the company is Rs. 13894.36 crore.

The promoters holding in the company stood at 54.90%, while Institutions and Non-Institutions held 29.90% and 15.19% respectively.

Eris Lifesciences has completed acquisition of 19% equity stake in Swiss Parenterals (Swiss) from the promoters of the company. Earlier, the company had acquired 51% equity stake in Swiss Parenterals. 

The acquisition of Swiss Parenterals will help company to strengthen India footprint through the launch of a domestic Injectables-focused Branded Formulations business. 

Eris Lifesciences develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives.